Sun Pharmaceutical Industries’ stock is trading at Rs. 1860.10, marking an increase of 11.05 points or 0.60% from its previous close at Rs. 1849.05 on the BSE.

The stock opened at Rs. 1852.50 and reached a high of Rs. 1875.00, with a low at Rs. 1852.50. So far, 55,990 shares have been traded on this counter.

This Group 'A' stock with a face value of Rs. 1 recorded its 52-week high of Rs. 1960.20 on September 30, 2024, and a 52-week low of Rs. 1069.00 on October 31, 2023. Over the past week, the stock’s high and low were Rs. 1919.80 and Rs. 1832.50, respectively. Sun Pharma’s current market cap stands at Rs. 4,47,403.99 crore.

Promoters hold 54.48% of the company's shares, while institutional and non-institutional investors hold 36.62% and 8.90%, respectively.

In a significant development, Sun Pharma has signed a global licensing agreement with Philogen S.p.A to commercialize Philogen’s innovative cancer immunotherapy, Fibromun (L19TNF). This therapy, aimed at soft tissue sarcoma and glioblastoma, is currently in pivotal clinical trials conducted by Philogen. The agreement grants Sun Pharma exclusive global commercialization rights, with Philogen managing trials and regulatory filings. The companies will share revenue post-commercialization, with Sun Pharma receiving 55% and Philogen 45%. Additional financial details were not disclosed.

Previously, on May 30, 2023, Sun Pharma and Philogen announced a licensing agreement to commercialize Nidlegy, a specialty product for melanoma, in Europe, Australia, and New Zealand. The first application for Nidlegy’s marketing authorization was submitted to the European Medicines Agency (EMA).

Sun Pharmaceutical Industries holds a prominent position as the world’s fourth-largest specialty generic pharmaceutical company and India’s leading pharmaceutical firm.